These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 2444164)

  • 21. [Treatment of hormone-resistant prostate cancer with estramustine phosphate (Estracyt)].
    Stridsklev IC; Fosså SD; Kaalhus O
    Tidsskr Nor Laegeforen; 1984 Oct; 104(28):1977-80. PubMed ID: 6388019
    [No Abstract]   [Full Text] [Related]  

  • 22. Treatment of prostatic carcinoma with estramustine phosphate (Estracyt).
    Benson RC
    Wis Med J; 1976 Sep; 75(9):S89-90. PubMed ID: 969557
    [No Abstract]   [Full Text] [Related]  

  • 23. [Treatment of advanced estrogen-resistant cancer of the prostate with estramustine phosphate. A phase-2 study].
    Trykker HU
    Ugeskr Laeger; 1985 Oct; 147(42):3310-2. PubMed ID: 4082315
    [No Abstract]   [Full Text] [Related]  

  • 24. [Stage D1 prostatic cancer benefited by a single regimen of Estracyt].
    Hata M
    Gan To Kagaku Ryoho; 1988 May; 15(5):1787-90. PubMed ID: 3369873
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of treatment with diethylstilbestrol-polyestradiol phosphate or estramustine phosphate (estracyt) on natural killer cell activity in patients with prostatic cancer.
    Kalland T; Haukaas S
    Invest Urol; 1981 May; 18(8):437-9. PubMed ID: 7228576
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rat prostatic weight regression in reaction to ketoconazole, cyproterone acetate, and RU 23908 as adjuncts to a depot formulation of gonadotropin-releasing hormone analogue.
    Lamberts SW; Uitterlinden P; de Jong FH
    Cancer Res; 1988 Nov; 48(21):6063-8. PubMed ID: 2844399
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen.
    Labrie F; Dupont A; Belanger A; Cusan L; Lacourciere Y; Monfette G; Laberge JG; Emond JP; Fazekas AT; Raynaud JP; Husson JM
    Clin Invest Med; 1982; 5(4):267-75. PubMed ID: 6819101
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Treatment of carcinoma of the prostate with analogs of LHRH].
    Rubio Herrera MA; Calle Fernández JR
    Rev Clin Esp; 1986 Nov; 179(8):407-11. PubMed ID: 2951782
    [No Abstract]   [Full Text] [Related]  

  • 29. Mode of action of estramustine phosphate in hormone dependent and hormone non-dependent prostate cancer.
    Hedlund PO
    Prog Clin Biol Res; 1985; 185A():197-202. PubMed ID: 3898129
    [No Abstract]   [Full Text] [Related]  

  • 30. The role of parenteral polyestradiol phosphate in the treatment of advanced prostatic cancer on the threshold of the new millennium.
    Mikkola A; Ruutu M; Aro J; Rannikko S; Salo J
    Ann Chir Gynaecol; 1999; 88(1):18-21. PubMed ID: 10230677
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of advanced oestrogen-resistant prostatic carcinoma with estramustine phosphate.
    Wong AL; McGeorge A; Abel BJ
    Clin Oncol; 1981 Jun; 7(2):163-5. PubMed ID: 7249439
    [No Abstract]   [Full Text] [Related]  

  • 32. [Hormonal and clinical efficacy of (D-Leu6)-des Gly-NH2(10)-LH.RH ethylamide against prostatic cancer].
    Imai K; Kumasaka F; Kobayashi M; Suzuki T; Takahashi O; Yamanaka H
    Hinyokika Kiyo; 1985 Dec; 31(12):2302-6. PubMed ID: 2938456
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Zoladex in prostatic carcinoma].
    Di Silverio F; Serio M
    Drugs Exp Clin Res; 1990; 16 Suppl():19-29. PubMed ID: 2150501
    [No Abstract]   [Full Text] [Related]  

  • 34. Oral estramustine phosphate. Prolonged therapy for advanced carcinoma of prostate.
    Catane R; Mittelman A; Kaufman J; Murphy GP
    N Y State J Med; 1976 Nov; 76(12):1978-81. PubMed ID: 1069190
    [No Abstract]   [Full Text] [Related]  

  • 35. Estramustine phosphate vs diethylstilbestrol in the treatment of stage D prostate cancer.
    Benson RC; Cummings K
    Prog Clin Biol Res; 1989; 303():177-86. PubMed ID: 2674984
    [No Abstract]   [Full Text] [Related]  

  • 36. [Clinical evaluation of CMA in the treatment of prostatic cancer].
    Fukuoka H; Goto A; Murai T; Satomi Y; Moriyama M; Senga Y; Shirai K; Nakao H
    Hinyokika Kiyo; 1986 Dec; 32(12):1821-30. PubMed ID: 2435131
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Pharmacology and metabolism of a new therapeutic drug for prostatic cancer "Estracyt"].
    Yamanaka H; Shida K
    Gan To Kagaku Ryoho; 1984 Mar; 11(3):537-44. PubMed ID: 6422861
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Equivalent and sufficient effects of leuprolide acetate and goserelin acetate to suppress serum testosterone levels in patients with prostate cancer.
    Fujii Y; Yonese J; Kawakami S; Yamamoto S; Okubo Y; Fukui I
    BJU Int; 2008 May; 101(9):1096-100. PubMed ID: 18190637
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Progress of endocrine therapy for prostate cancer and results].
    Kanetake H
    Gan To Kagaku Ryoho; 1996 Mar; 23(4):413-7. PubMed ID: 8678491
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Estramustine phosphate: a specific chemotherapeutic agent?
    Von Hoff DD; Rozencweig M; Slavik M; Muggia FM
    J Urol; 1977 Apr; 117(4):464-6. PubMed ID: 850319
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.